The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.

The uncommon mutations in the EGFR (the epithelial growth factor receptor) gene include a heterogeneous group of genomic alterations within exons 18-21. The clinical response of patients with such mutations to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, however, remains unclear. We herein report a case of advanced lung adenocarcinoma harboring complex exon 18 G719X (Gly719Xaa) and exon 20 S768I (Ser768Ile) mutations. The patient started to receive afatinib and has exhibited good response without progression for 12 months. Second-generation EGFR-TKIs might be an optimal treatment option for non-small cell lung cancers harboring these types of rare EGFR mutation.

Introduction

Numerous studies have demonstrated the superiority of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) over standard chemotherapy in regard to progression-free survival (PFS) and the response to treatment in non-small cell lung cancers (NSCLCs) with sensitive EGFR mutations. Thus, EGFR-TKI is currently the mainstay first-line systemic therapy for advanced EGFR-mutant NSCLC.

The two most common EGFR mutations, exon 19 deletion (del19) and the Leu858Arg point mutation in exon 21 (L858R), account for 90% of all mutations in this gene. The remaining 10% of EGFR mutations (so-called uncommon mutations), are a heterogeneous group of genomic alterations that occur within exons 18-21.

Recently, the EGFR-TKI afatinib has been reported to show anti-tumor activity in patients with NSCLC harboring such uncommon EGFR mutations (1). We herein report a case of NSCLC harboring rare complex exon 18 (G719X) and exon 20 (S768I) mutations, which responded well to afatinib monotherapy.

Case Report

A 72-year-old female patient was referred to our hospital due to continuous cough and sputum. Routine laboratory examinations revealed high levels of serum CYFRA (4.4 ng/mL) and SLX (88.1 U/mL). Chest computed tomography revealed a primary lung tumor in the right S1a and an irregular, thickened interlobular septum and bronchovascular interstitium in the right upper and middle lobes (Fig. 1), which were considered to be primary lung cancer and carcinomatous lymphangitis, respectively. Clinical cT4N3M0 stage IIIB (UICC TNM Classification, 7th Edition) adenocarcinoma of the lung was diagnosed on the basis of a bronchoscopic tumor biopsy; there was no evidence of distant metastasis.

Figure 1.

Chest computed tomography scans prior to afatinib treatment, showing a primary lung tumor in the right S1a, and an irregular, thickened interlobular septum and bronchovascular interstitium in the right upper lobe.

Complex G719X (Gly719Xaa) and S768I (Ser768Ile) mutations were detected in cytological samples by EGFR mutation testing. Based on recent reports demonstrating the anti-tumor activity of afatinib (a second-generation EGFR-TKI) in patients with uncommon EGFR mutations, we recommended this therapy to the patient. After obtaining her consent, the patient was started on afatinib (40 mg/day); however serious adverse events, including diarrhea (Grade 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0), rash (Grade 2), stomatitis (Grade 2), and nausea (Grade 3) necessitated the temporary cessation of treatment. Subsequently, the afatinib dosage was reduced twice to relieve adverse events, and the patient currently receives a dose of 20 mg/day (Fig. 2), which has resulted in substantial tumor shrinkage (Fig. 3). At 12 months since the start of afatinib treatment, no progressive disease has been observed in the patient.

Figure 2.

The clinical course of afatinib treatment. The dose of afatinib was reduced twice to relieve adverse clinical events. The patient currently receives afatinib (20 mg/day).

Figure 3.

Chest computed tomography scans following afatinib treatment, showing the shrinkage of the primary lung tumor and the disappearance of carcinomatous lymphangitis.

Discussion

Generally, NSCLC patients with common EGFR mutations (such as del19 or L858R in exon 21) exhibit a dramatic response to EGFR-TKIs. Other mutations in exons 18-21, including complex mutations, are considered rare and the clinical response of such patients to EGFR-TKI treatment has remained unclear. Complex G719X and S768I mutations, which were detected in the current case, have previously been reported to be rare in the combined analysis of the LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 NSCLC cohorts (NCT00525148, NCT00949650, and NCT01121393, respectively); only five patients with these mutations were found among 600 afatinib-treated EGFR-mutant NSCLC cases (5/600 cases, 0.83%) (1). Among the uncommon mutations that were documented in the same analysis (n=75 patients), G719X and S768I mutations only represented 6.6% of the rare variants (5/75 cases) (1). In another report, complex G719X and S768I mutations were detected in 10/161 cases with uncommon EGFR mutations (6.2%) (2).

To date, several studies have reported the distinct clinical effectiveness of first-generation EGFR-TKIs in the treatment of NSCLC cases involving uncommon mutations (2-6). The post-hoc analysis of NEJ002 (UMIN C000000376) demonstrated that the overall survival and PFS of gefitinib-treated patients with uncommon EGFR mutations (G719X and L861Q) were shorter in comparison to those with common mutations (6). Among the 10 NSCLC cases with G719X and S768I mutations, five patients exhibited partial responses to EGFR-TKI, whereas the other five cases developed resistance to therapy. Intriguingly, patients with complex uncommon EGFR mutations (G719X and L861Q, or G719X and S768I) had significantly longer PFS in comparison to patients with a single uncommon mutation (2). With respect to the individual mutations observed in the current case, first-generation EGFR-TKIs are considered to be moderately effective in patients with G719X (4), while S768I has been associated with a poor response to first generation EGFR-TKIs, especially gefitinib (7).

In preclinical experiments, Kobayashi et al. showed that EGFR exon 18 mutations are associated with unique sensitivity to afatinib and neratinib (second-generation EGFR-TKIs), in comparison to first- and third-generation TKIs (8), suggesting that lung cancer patients with exon 18 mutations could be good candidates for treatment with afatinib. In addition, Banno et al. demonstrated that stably transfected Ba/F3 cell lines harboring an S768I mutation were sensitive to afatinib, suggesting that afatinib might also be effective in NSCLC patients with S768I mutations (9). The activity of afatinib in patients with uncommon EGFR mutations in the LUX-Lung clinical trials has been retrospectively reviewed (1). In this analysis, the uncommon mutation cohort was divided into three groups: point mutations or duplications in exons 18-21, de novo Thr790Met (T790M) mutations in exon 20, and insertion mutations in exon 20. Intriguingly, the best response to afatinib was noted in patients with point mutations or duplications in exons 18-21. In addition, Tanizaki et al. reported that afatinib was clinically effective for the treatment of NSCLC harboring EGFR mutations G719C and S768I, as well as KRAS E49K mutation (10). These findings encouraged us to initiate afatinib treatment in the present case (a patient with uncommon EGFR mutations), which led to remarkable tumor shrinkage and symptom improvement.

Afatinib-related adverse events included diarrhea, rash/acne, stomatitis and nail effects. The diarrhea and rash/acne associated with afatinib monotherapy has been reported - in several clinical trials - to be more pronounced in comparison to first-generation EGFR-TKIs. Rash can have a negative impact on the quality of life, and cautious dermatology care is recommended. Likewise, TKI-induced diarrhea should be monitored carefully. When patients present with such severe toxicities, afatinib administration is interrupted and typically resumed at a reduced dose upon recovery. Yang et al. reported that, in the LUX-Lung 3 and LUX-Lung 6 studies, the median PFS in patients in whom the dose was reduced during the first 6 months of afatinib treatment was similar to that of the patients in whom the dose was not reduced in the first 6 months of treatment (11.3 vs. 11.0 months, respectively) (11). Thus, the tolerability-guided dose adjustment of afatinib appears to reduce the incidence and severity of treatment-related adverse events without affecting efficacy. Afatinib dose management was similarly applied in the present case, and the patient has exhibited good response to afatinib (20 mg/day), without progression, for the last 12 months.

In conclusion, we herein reported the case of an NSCLC patient harboring rare complex G719X and S768I mutations, who responded to afatinib monotherapy. Based on these findings, second-generation EGFR-TKIs might be considered as an optimal treatment option for NSCLC cases harboring this type of EGFR mutation profile. A further analysis of the efficacy of EGFR-TKIs in such cases will lay the groundwork for developing optimized treatment protocols for NSCLC patients with uncommon EGFR mutations.

Author's disclosure of potential Conflicts of Interest (COI).

Satoshi Oizumi: Honoraria, AstraZeneca and Eli Lilly.